4.8 Article

Structural basis of antagonizing the vitamin K catalytic cycle for anticoagulation

Journal

SCIENCE
Volume 371, Issue 6524, Pages 43-+

Publisher

AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.abc5667

Keywords

-

Funding

  1. National Heart, Lung, and Blood Institute (NHLBI) [R01 HL121718]
  2. W. M. Keck Foundation (Forefront of Science Award)
  3. Children's Discovery Institute [MCII 2020-854]
  4. National Eye Institute (NEI) [R21 EY028705]
  5. National Institute of General Medical Sciences (NIGMS) [R01 GM131008]
  6. NIGMS [P30 GM124165]
  7. NIH-ORIP [HEI S10OD021527]
  8. U.S. Department of Energy (DOE) [DE-AC02-06CH11357]

Ask authors/readers for more resources

Vitamin K antagonists act by mimicking key interactions and conformational changes required for the VKOR catalytic cycle, which is crucial for their anticoagulant effect.
Vitamin K antagonists are widely used anticoagulants that target vitamin K epoxide reductases (VKOR), a family of integral membrane enzymes. To elucidate their catalytic cycle and inhibitory mechanism, we report 11 x-ray crystal structures of human VKOR and pufferfish VKOR-like, with substrates and antagonists in different redox states. Substrates entering the active site in a partially oxidized state form cysteine adducts that induce an open-to-closed conformational change, triggering reduction. Binding and catalysis are facilitated by hydrogen-bonding interactions in a hydrophobic pocket. The antagonists bind specifically to the same hydrogen-bonding residues and induce a similar closed conformation. Thus, vitamin K antagonists act through mimicking the key interactions and conformational changes required for the VKOR catalytic cycle.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available